Ruxolitinib (JAK1/JAK2), Tofacitinib (JAK1/JAK3) and Ritlecitinib (JAK3 selective) were selected in the current study based on their clinical efficacies in treating lymphoma and autoimmune diseases. Here, JAK2 is linked to lymphoma.